Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~To be eligible for inclusion into the study, a patient must meet the following criteria:~* Subject has clinically confirmed diagnosis of active Notalgia Paresthetica;~* Subject has a history of chronic pruritus due to Notalgia Paresthetica;~* Subject has moderate to severe pruritus;~* Female subject is not pregnant or nursing during any period of the study.~Key Exclusion Criteria:~A patient will be excluded from the study if any of the following criteria are met:~* Subject has pruritus attributed to a cause other than Notalgia Paresthetica;~* Subject has any clinically significant medical condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Difelikefalin 2.0 mg (Type: ACTIVE_COMPARATOR): Oral difelikefalin 2.0 mg tablet administered twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Oral placebo tablet administered twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).